Building or investing in the bispecific antibody market?

Big drug makers want bispecific antibodies badly in 2026, and they're paying whoever has the best ones, in Europe or in China.

We've found a lot of interesting signals. For example, in October 2025, Takeda agreed to pay China's Innovent $1.2B upfront in a deal built around IBI363, a bispecific that blocks PD-1 and boosts IL-2 signaling. Then in December, Genmab took control of Merus, the Dutch maker of the head and neck cancer bispecific petosemtamab, in a deal valued at about $8B. Pharma is spending heavily on two-target antibodies, whether they come from a Chinese lab or a European biotech.

In this section, we look at why pharma is paying so much for bispecifics now, why so many of them come from China, and what the first FDA decision on a PD-1 and VEGF bispecific, expected in November 2026, could mean for the rest of the field.

Many cancers learn to hide from the immune system, and one-target antibodies often stop working. Bispecifics try to fix that by doing two jobs at once, but they bring new problems of their own.

We compare six types of bispecific companies, from T-cell engager developers and dual checkpoint players to platforms that license their antibody formats. Their buyers are mostly big pharma, along with cancer centers and, more and more, immunology teams. Then we rank their biggest pains, like immune reactions that keep patients in hospital after the first doses, tumors that lose the target, and molecules that are hard to make cleanly.

You'll see which of these problems are worth a licensing deal today, and which still need better data from patients.

Some bispecific companies sell their own drugs. Many more live on upfront payments, milestones and royalties from big pharma, or license their antibody formats to anyone who wants to build with them.

We compare who pays, when the money comes in and what each path costs. A company that owns its drug keeps the upside but funds years of trials. A format platform can sign many partners, though most of its income depends on their success. T-cell engagers add costs after launch, because the first doses often need a hospital stay. And many Chinese biotechs now license their best molecules abroad, usually for a modest upfront and a much larger total that depends on milestones.

You'll see when selling rights early makes more sense than keeping a drug, and what a big headline deal value is really worth.

Approvals tell only part of the story. Here, we look at the forces that push bispecifics toward more patients.

Some drivers are easy to spot: more approvals in blood cancers, moves into lung and other solid tumors, and big pharma needing new drugs before its best sellers lose patent protection. Others feed each other. Shots under the skin and fewer hospital stays make these drugs easier to use in regular clinics. Early T-cell engager results in autoimmune diseases open up much larger patient groups. And each licensing deal from China makes the next one easier to sign.

Before building or investing, you should know what it takes for a bispecific to beat the standard drug in a head-to-head trial, and to be given safely outside a big cancer center.

Amgen and Summit Therapeutics get most of the headlines in bispecifics, one for its T-cell engagers and the other for its PD-1 and VEGF drug, but they're far from the whole field.

Many of the most interesting players are little known. Some only license antibody formats and never run a trial of their own. Others design T-cell engagers that stay switched off until they reach a tumor, or test them in lupus and other autoimmune diseases. A growing number are Chinese biotechs whose molecules end up in Western pipelines under a new name.

Following them is tricky, because the same molecule can carry three names in a few years: a code in China, a new one after a license, and a brand at launch. Deal terms are often partly private, and many results come from small early trials that are hard to compare.

Below, you'll find the market grids and ecosystem maps we've built to show who works on which format and target, and where new companies are finding room.

Akeso, Zymeworks, Harpoon Therapeutics… some bispecific makers have already been rewarded, but not in the same way.

Akeso brought two bispecifics to market in China and licensed ivonescimab to Summit for the US, Europe and Japan. Zymeworks partnered zanidatamab, which grabs two different spots on HER2, with Jazz, and the drug won US approval in biliary tract cancer. Harpoon was bought by Merck for its T-cell engagers before any of them reached the market. Each picked a different moment to share or sell.

We'll look at how these teams decided when to keep a drug, when to license it, and when to sell the whole company.